Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

在新兴的生物医药领域，研究人员和制药公司持续努力寻求有效的疾病预防和治疗方法，尤其是在艾滋病这样的重大全球健康挑战面前。近期，吉利德科学（Gilead Sciences）公司宣布了一项令人振奋的进展：仅需每年注射一次的长效HIV预防疗法lenacapavir，目前已顺利进入阶段三的临床试验。此外，默沙东（MSD）公司和ViiV ...

吉利德（Gilead）计划跳过 II 期研究，直接启动每年一次注射的 lenacapavir III 期临床试验；葛兰素史克（GSK）与 ViiV 医疗（ViiV Healthcare）则在公布长效抗病毒药物的积极早期数据后，宣布推进后续开发。

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...